New help, new hope

Research output: Contribution to journalReview article

Abstract

Recent advances in the treatment of multiple sclerosis (MS) are the immunomodulatory agents interferon beta-1b, interferon beta-1a, and glatiramer. These drugs reduce the rate of relapse in relapsing-remitting MS; in addition, the interferons slow the progression of the disease. The earlier in the disease these drugs are started, the better the long-term results. Thus, timely diagnosis and treatment are more important than ever before. The diagnosis is based on clinical findings that are supported by the presence of CNS lesions on MRI. Key symptoms that signal MS - particularly in young adults - include unilateral vision loss, diplopia that last for days or weeks, and hemiparesis that has an insidious or slow onset.

Original languageEnglish (US)
Pages (from-to)1085-1094
Number of pages10
JournalConsultant
Volume40
Issue number6
StatePublished - May 1 2000

Fingerprint

Multiple Sclerosis
Relapsing-Remitting Multiple Sclerosis
Diplopia
Interferon-beta
Paresis
Pharmaceutical Preparations
Interferons
Disease Progression
Young Adult
Recurrence
Therapeutics
Interferon beta-1b
Glatiramer Acetate
Interferon beta-1a

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Hess, D. C. (2000). New help, new hope. Consultant, 40(6), 1085-1094.

New help, new hope. / Hess, David C.

In: Consultant, Vol. 40, No. 6, 01.05.2000, p. 1085-1094.

Research output: Contribution to journalReview article

Hess, DC 2000, 'New help, new hope', Consultant, vol. 40, no. 6, pp. 1085-1094.
Hess DC. New help, new hope. Consultant. 2000 May 1;40(6):1085-1094.
Hess, David C. / New help, new hope. In: Consultant. 2000 ; Vol. 40, No. 6. pp. 1085-1094.
@article{9bb9186afa394df8b386240b01da1ab0,
title = "New help, new hope",
abstract = "Recent advances in the treatment of multiple sclerosis (MS) are the immunomodulatory agents interferon beta-1b, interferon beta-1a, and glatiramer. These drugs reduce the rate of relapse in relapsing-remitting MS; in addition, the interferons slow the progression of the disease. The earlier in the disease these drugs are started, the better the long-term results. Thus, timely diagnosis and treatment are more important than ever before. The diagnosis is based on clinical findings that are supported by the presence of CNS lesions on MRI. Key symptoms that signal MS - particularly in young adults - include unilateral vision loss, diplopia that last for days or weeks, and hemiparesis that has an insidious or slow onset.",
author = "Hess, {David C}",
year = "2000",
month = "5",
day = "1",
language = "English (US)",
volume = "40",
pages = "1085--1094",
journal = "Consultant",
issn = "0010-7069",
publisher = "Cliggott Publishing Co.",
number = "6",

}

TY - JOUR

T1 - New help, new hope

AU - Hess, David C

PY - 2000/5/1

Y1 - 2000/5/1

N2 - Recent advances in the treatment of multiple sclerosis (MS) are the immunomodulatory agents interferon beta-1b, interferon beta-1a, and glatiramer. These drugs reduce the rate of relapse in relapsing-remitting MS; in addition, the interferons slow the progression of the disease. The earlier in the disease these drugs are started, the better the long-term results. Thus, timely diagnosis and treatment are more important than ever before. The diagnosis is based on clinical findings that are supported by the presence of CNS lesions on MRI. Key symptoms that signal MS - particularly in young adults - include unilateral vision loss, diplopia that last for days or weeks, and hemiparesis that has an insidious or slow onset.

AB - Recent advances in the treatment of multiple sclerosis (MS) are the immunomodulatory agents interferon beta-1b, interferon beta-1a, and glatiramer. These drugs reduce the rate of relapse in relapsing-remitting MS; in addition, the interferons slow the progression of the disease. The earlier in the disease these drugs are started, the better the long-term results. Thus, timely diagnosis and treatment are more important than ever before. The diagnosis is based on clinical findings that are supported by the presence of CNS lesions on MRI. Key symptoms that signal MS - particularly in young adults - include unilateral vision loss, diplopia that last for days or weeks, and hemiparesis that has an insidious or slow onset.

UR - http://www.scopus.com/inward/record.url?scp=0033936429&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0033936429&partnerID=8YFLogxK

M3 - Review article

VL - 40

SP - 1085

EP - 1094

JO - Consultant

JF - Consultant

SN - 0010-7069

IS - 6

ER -